Sanofi is suing Merck Sharp & Dohme Corp. for infringing Sanofi’s patents on its top-selling injectable diabetes drug Lantus (Sanofi-Aventis U.S. LLC v. Merck Sharp & Dohme Corp.complaint filed).
The Paris-based company sued Merck in the U.S. District Court for the District of Delaware Sept. 16, alleging that Merck’s bid to make a generic version of the long-acting insulin drug infringes 10 of Sanofi’s Lantus-related patents. Those patents relate to Lantus and Lantus SolarStar, the pre-filled pen used to inject the drug.
The suit is Sanofi’s latest attempt to try to delay the full force of generic competition ...
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.